TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial

Per Pfeiffer, Mette Yilmaz, Sören Möller, Daniela Zitnjak, Merete Krogh, Lone Nørgård Petersen, Laurids Østergaard Poulsen, Stine Braendegaard Winther, Karina Gravgaard Thomsen, Camilla Qvortrup

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

6 Citationer (Scopus)
OriginalsprogEngelsk
TidsskriftThe Lancet. Oncology
Vol/bind21
Udgave nummer3
Sider (fra-til)412-420
Antal sider9
ISSN1470-2045
DOI
StatusUdgivet - mar. 2020

Fingeraftryk Dyk ned i forskningsemnerne om 'TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial'. Sammen danner de et unikt fingeraftryk.

  • Citationsformater